tezosentan has been researched along with Heart Failure in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (82.93) | 29.6817 |
| 2010's | 7 (17.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourge, RC; Cleland, JGF; Cotter, G; Davison, BA; Edwards, C; Jondeau, G; Kobrin, I; McMurray, JJV; Metra, M; Milo, O; O'Connor, CM; Parker, JD; Rainisio, M; Senger, S; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Cromie, M; D'Armini, AM; Denault, AY; Lindberg, E; Michler, RE; Pearl, RG; Rao, V; Seitelberger, R; Tsui, SS | 1 |
| Bourge, RC; Cleland, JG; Cotter, G; Davison, BA; Jondeau, G; Kobrin, I; Krum, H; McMurray, JJ; Metra, M; Milo, O; O'Connor, CM; Parker, JD; Rainisio, M; Senger, S; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Abukar, Y; May, CN; Ramchandra, R | 1 |
| Bourge, RC; Cleland, JG; Cotter, G; Davison, BA; Edwards, C; Jondeau, G; Kobrin, I; Krum, H; McMurray, JJ; Metra, M; Milo, O; O'Connor, CM; Parker, JD; Rainisio, M; Senger, S; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Bourge, RC; Cleland, JGF; Cotter, G; Davison, BA; Jondeau, G; Krum, H; McMurray, JJV; Metra, M; Milo, O; O'Connor, CM; Parker, JD; Senger, S; Shoaib, A; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Cotter, G; Dittrich, H; Felker, GM; Metra, M; Milo-Cotter, O; Teerlink, JR; Voors, AA; Weatherley, B | 1 |
| Cho, KR; Jo, WM; Kim, HJ; Ryu, SM | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
| Adams, KF; Frey, A; Gattis, WA; Gheorghiade, M; Kobrin, I; O'Connor, CM; Shah, MR | 1 |
| Caspi, A; Cotter, G; Frey, A; Kaluski, E; Kaplan, S; Kobrin, I; Krakov, O; Krakover, R; Marmor, A; Milo, O; Vered, Z; Zimlichman, R | 1 |
| Teerlink, JR | 2 |
| Adams, KF; Frey, A; Gattis, WA; Gheorghiade, M; O'Connor, CM; Shah, MR | 1 |
| Lüscher, TF; Spieker, LE | 1 |
| Gottlieb, SS | 1 |
| Adams, KF; Chandler, B; Frey, A; Gattis, WA; Gheorghiade, M; Hasselblad, V; Kobrin, I; O'Connor, CM; Rainisio, M; Shah, MR; Teerlink, J | 1 |
| Colucci, WS; Cotter, G; Elkayam, U; Frey, A; Kobrin, I; Lewis, BS; Pratt, C; Rainisio, M; Stangl, K; Teerlink, JR; Torre-Amione, G; Young, JB | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Seymour, AM | 1 |
| Boerrigter, G; Burnett, JC | 1 |
| Gums, JG; Tovar, JM | 1 |
| Krum, H; Liew, D | 1 |
| Adams, KF; Gattis, WA; Gheorghiade, M; Hasselblad, V; Kobrin, I; O'Connor, CM | 1 |
| Graham, CA | 1 |
| Cotter, G; Dingemanse, J; Frey, A; Kaluski, E; Kaplan, S; Kobrin, I; Milo-Cotter, O; Neuhart, E; Pacher, R; Perchenet, L; Rainisio, M; Richter, C; Stangl, K; Torre-Amione, G; Vered, Z | 1 |
| Dunlap, ME; Ibrahim, OA | 1 |
| Bourge, RC; Cleland, JG; Cotter, G; Frey, A; Jondeau, G; Kobrin, I; Krum, H; McMurray, JJ; Metra, M; O'Connor, CM; Parker, JD; Rainisio, M; Teerlink, JR; Torre-Amione, G; Van Veldhuisen, DJ | 1 |
| Gheorghiade, M; Mebazaa, A; Teerlink, JR | 1 |
| Mehra, MR | 1 |
| Böttiger, BW; Motsch, J; Rauch, H | 1 |
| Bourge, RC; Cleland, JG; Cotter, G; Frey, A; Jondeau, G; Kobrin, I; Krum, H; Lewsey, J; McMurray, JJ; Metra, M; O'Connor, CM; Parker, JD; Rainisio, M; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Duchman, SM; Kalra, D; Thohan, V; Torre-Amione, G | 1 |
| Bozkurt, B; Durand, J; Kobrin, I; Mann, DL; Pratt, CM; Torre-Amione, G; Young, JB | 1 |
| Clark, A; Cleland, JG; Crabbe, S; Ford, S; Houghton, T; Louis, A; Thackray, S | 1 |
| Bertel, O; Cotter, G; Guyene, TT; Kiowski, W; Kobrin, I; Reisin, L; Schalcher, C | 1 |
| Clozel, JP; Clozel, M; Ding, SS; Hess, P; Qiu, C | 1 |
| Durand, JB; Kobrin, I; Nagueh, S; Pratt, C; Torre-Amione, G; Vooletich, MT | 1 |
| Caspi, A; Cotter, G; Jafari, J; Kaluski, E; Kiowski, W; Kobrin, I; Krakover, R; Marmor, A; Milovanov, O; Reisin, L; Vered, Z | 1 |
| Cheng, TO | 1 |
| Clozel, JP; Clozel, M; Hess, P; Qiu, CB; Qiu, CS | 1 |
16 review(s) available for tezosentan and Heart Failure
| Article | Year |
|---|---|
Vasodilators in the treatment of acute heart failure: what we know, what we don't.
Topics: Acute Disease; Atrial Natriuretic Factor; Benzoates; Elapid Venoms; Endothelin-1; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Nitrates; Peptide Fragments; Prognosis; Pyridines; Receptors, Endothelin; Relaxin; Tetrazoles; Vasoconstriction; Vasodilator Agents | 2009 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
The development of new medical treatments for acute decompensated heart failure.
Topics: Acute Disease; Cardiotonic Agents; Cohort Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Multicenter Studies as Topic; Natriuretic Agents; Natriuretic Peptide, Brain; Placebos; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Endothelin; Simendan; Tetrazoles; Time Factors; Vasodilator Agents | 2002 |
Will endothelin receptor antagonists have a role in heart failure?
Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome | 2003 |
Endothelin in neurohormonal activation in heart failure.
Topics: Animals; Carboxylic Acids; Endothelin Receptor Antagonists; Endothelins; Endothelium, Vascular; Heart; Heart Failure; Humans; Indans; Neurotransmitter Agents; Pyridines; Tetrazoles; Vasodilator Agents | 2003 |
Tezosentan in the treatment of acute heart failure.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Heart Failure; Humans; Pyridines; Tetrazoles | 2003 |
New and emerging drug therapies for the management of acute heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents; Vasopressins | 2003 |
Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
Topics: Acute Disease; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Critical Illness; Developed Countries; Diuretics; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Oxygen Inhalation Therapy; Patient Selection; Pulmonary Edema; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2004 |
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Pharmacology of new agents for acute heart failure syndromes.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Pyridazines; Pyridines; Simendan; Syndrome; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
Newer approaches to the pharmacological management of heart failure.
Topics: Calcium Signaling; Cardiotonic Agents; Cardiovascular Agents; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyridazines; Pyridines; Simendan; Tetrazoles | 2006 |
Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure.
Topics: Animals; Disease Models, Animal; Disease Progression; Dogs; Drug Evaluation, Preclinical; Endothelin-1; Heart Failure; Hemodynamics; Humans; Oxygen Consumption; Prognosis; Pyridines; Rabbits; Rats; Survival Analysis; Tetrazoles | 2000 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol; Cholesterol; Cytokines; Endothelins; Heart Failure; Humans; Indans; Injections, Intravenous; Myocardial Infarction; Propanolamines; Pyridines; Tetrazoles; United States; Vasodilator Agents | 2001 |
18 trial(s) available for tezosentan and Heart Failure
| Article | Year |
|---|---|
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
Topics: Acute Disease; Aged; Blood Pressure; Cause of Death; Europe; Female; Heart Failure; Hospitalization; Humans; Male; Ontario; Pyridines; Survival Rate; Systole; Tetrazoles; Treatment Outcome; United States; Vasodilator Agents | 2018 |
Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double-Blind Method; Endpoint Determination; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Middle Aged; Pyridines; Tetrazoles; Vasodilator Agents; Ventricular Dysfunction, Right; Young Adult | 2013 |
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Outcome Assessment, Health Care; Patient Admission; Pyridines; Tetrazoles; Vasodilator Agents | 2014 |
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS.
Topics: Acute Disease; Aged; Analysis of Variance; Double-Blind Method; Female; Heart Failure; Hospital Mortality; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Multivariate Analysis; Patient Discharge; Patient Readmission; Prognosis; Proportional Hazards Models; Pyridines; Survival Analysis; Tetrazoles; Time Factors; Treatment Outcome | 2016 |
Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (V
Topics: Acute Disease; Aged; Biomarkers; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Injections, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Admission; Patient Discharge; Prognosis; Pyridines; Receptors, Endothelin; Retrospective Studies; Survival Rate; Tetrazoles; Time Factors; Troponin I; United States; Vasodilator Agents | 2017 |
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).
Topics: Acute Disease; Adult; Child; Coronary Disease; Double-Blind Method; Endothelins; Female; Heart Failure; Humans; Myocardial Infarction; Pyridines; Recurrence; Syndrome; Tetrazoles; Vasodilator Agents | 2002 |
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Topics: Double-Blind Method; Echocardiography; Endothelin Receptor Antagonists; Heart Failure; Humans; Injections, Intravenous; Prospective Studies; Pulmonary Edema; Pyridines; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
Topics: Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Myocardial Ischemia; Pyridines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Recurrence; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
Topics: Acute Disease; Aged; Coronary Disease; Double-Blind Method; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Pyridines; Syndrome; Tetrazoles; Vasodilator Agents | 2003 |
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridines; Tetrazoles | 2003 |
Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).
Topics: Acute Disease; Aged; Coronary Disease; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Male; Multicenter Studies as Topic; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tetrazoles; Troponin I; Vasodilator Agents | 2004 |
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
Topics: Aged; Double-Blind Method; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelins; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridines; Tetrazoles | 2004 |
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
Topics: Acute Disease; Aged; Cardiac Output; Double-Blind Method; Dyspnea; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Pulmonary Wedge Pressure; Pyridines; Tetrazoles; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2007 |
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Female; Heart Failure; Heart Function Tests; Heart Rate; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridines; Receptor, Endothelin A; Receptor, Endothelin B; Tetrazoles; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2001 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol; Cholesterol; Cytokines; Endothelins; Heart Failure; Humans; Indans; Injections, Intravenous; Myocardial Infarction; Propanolamines; Pyridines; Tetrazoles; United States; Vasodilator Agents | 2001 |
The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Epinephrine; Female; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyridines; Tetrazoles; Vasodilator Agents | 2001 |
A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
Topics: Acute Disease; Aged; Dobutamine; Double-Blind Method; Drug Tolerance; Echocardiography, Doppler; Endothelin Receptor Antagonists; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Pyridines; Safety; Tetrazoles | 2001 |
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Hypotension; Infusions, Intravenous; Male; Middle Aged; Probability; Pyridines; Receptors, Endothelin; Reference Values; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Vascular Resistance | 2001 |
8 other study(ies) available for tezosentan and Heart Failure
| Article | Year |
|---|---|
Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure.
Topics: Animals; Arterial Pressure; Baroreflex; Biomarkers; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Infusions, Intravenous; Pyridines; Sheep; Signal Transduction; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Time Factors; Up-Regulation | 2016 |
Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.
Topics: Animals; Cardiomyopathies; Coronary Vessels; Disease Models, Animal; Doxorubicin; Endothelin Receptor Antagonists; Heart Failure; Hypertrophy; Male; Pressure; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Reperfusion Injury; Tetrazoles; Vasodilator Agents; Ventricular Function, Left | 2009 |
The neurohormonal paradigm: have we gone too far?
Topics: Heart Failure; Humans; Neurotransmitter Agents; Pyridines; Tetrazoles; Vasodilator Agents | 2003 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Defibrillators, Implantable; Endpoint Determination; Health Education; Heart Failure; Hemodynamics; Humans; Metoprolol; Propanolamines; Pyridines; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Topics: Acute Disease; Adult; Double-Blind Method; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Male; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Research Design; Tetrazoles; Vasodilator Agents | 2005 |
Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
Topics: Animals; Blood Pressure; Endothelin Receptor Antagonists; Heart Failure; Heart Rate; Hemodynamics; Kidney; Male; Pyridines; Rats; Rats, Wistar; Receptors, Endothelin; Tetrazoles; Vascular Resistance; Vasodilator Agents; Ventricular Function, Left | 2001 |
Endothelin receptor blockade in congestive heart failure.
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Phenylpropionates; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2001 |
Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug Synergism; Enalapril; Endothelin Receptor Antagonists; Heart Failure; Heart Rate; Hemodynamics; Male; Myocardial Infarction; Pyridines; Rats; Rats, Wistar; Tetrazoles | 2001 |